Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059172 | 0.87 | CYP19A1 (0.50) | — | |
| SCHEMBL13293827 | 0.85 | CASP1 (0.38) | L3MBTL1CASP1HSD17B10CA2CNR1 | |
| SCHEMBL8320013 | 0.85 | ESR1 (0.45) | CNR1CNR2KDM4E | |
| SCHEMBL1525445 | 0.85 | MAOB (0.50) | MEN1KMT2ALMNAGAACYP1A2 | |
| SCHEMBL1525371 | 0.83 | DRD2 (0.47) | L3MBTL1CASP1HSD17B10CNR1CNR2 | |
| SCHEMBL14582859 | 0.82 | PDCD1 (0.44) | L3MBTL1CNR1CNR2HTTGAA | |
| SCHEMBL1525558 | 0.82 | CA5A (0.41) | L3MBTL1CA2MEN1KMT2ACA1 | |
| SCHEMBL3242065 | 0.82 | NPC1 (0.56) | MEN1KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13672823 | 0.81 | VDR (0.59) | L3MBTL1MEN1KMT2AHTTTSHR | |
| SCHEMBL11436624 | 0.80 | CNR1 (0.43) | L3MBTL1CASP1HSD17B10CA2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408852-B2 | Method of lowering serum uric acid levels with (S)-tofisopam | PHARMOS CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408852-B2 | Method of lowering serum uric acid levels with (S)-tofisopam | PHARMOS CORPORATION (US) | 2016-08-09 | — | — | US | disclosed |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | PHARMOS CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | PHARMOS CORPORATION (US) | 2013-02-21 | — | — | US | disclosed |
| EP-1581206-A4 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | VELA ACQUISITION CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1575521-A4 | PHARMACEUTICAL COMPOSITION OF 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND USES THEROF | VELA ACQUISITION CORP (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1567162-A4 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA ACQUISITION CORP (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| EP-1689408-A1 | TREATMENT OF INFLAMMATORY DISORDERS OF THE EPITHELIUM WITH LOW DOSE 2,3-BENZODIAZEPINES | Vela Pharmaceuticals Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2004069155-A2 | PHARMACEUTICAL COMPOSITION OF 1-(3-HYDROXY-4-METHOXYPHENYL)-4-METHYL-5-ETHYL-7,8-DIMETHOXY-5H-2,3-BENZODIAZEPINE AND USES THEROF | VELA PHARMACEUTICALS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040152695-A1 | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof | VELA PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | VELA PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| WO-2004050080-A1 | TREATMENT OF INFLAMMATORY DISORDERS WITH 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050616-A2 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050615-A2 | METHOD OF INCREASING NEUTROPHIL PRODUCTION USING 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6638928-B1 | Benzodiazepines administered for irritable bowel syndrome and nonulcer dyspepsia. | VELA PHARMACEUTICALS, INC. | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138209-A1 | Treatment of inflammatory disorders with 2,3- benzodiazepines | LTB4R2, LTB4R, GABRA4 | L3MBTL1 2232/4885CASP1 598/4885HSD17B10 445/4885 |
| US-20040106602-A1 | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines | LTB4R2, LTB4R, PTGER4 | L3MBTL1 2234/4885CASP1 1033/4885HSD17B10 470/4885 |
| US-20040152695-A1 | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof | GABRA4, GABRA2, GABRB2 | L3MBTL1 4111/4885CASP1 3656/4885HSD17B10 438/4885 |
| US-20040106601-A1 | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines | OPRL1, OPRD1, GABRR1 | L3MBTL1 4497/4885CASP1 1224/4885HSD17B10 1054/4885 |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | GABBR2, GABBR1, GABRB3 | L3MBTL1 2769/4885CASP1 754/4885HSD17B10 958/4885 |
| US-20040138210-A1 | Method of increasing neutrophil production using 2,3-benzodiazepines | GABRR1, GABRA1, GABRA3 | L3MBTL1 3706/4885CASP1 844/4885HSD17B10 1293/4885 |
| US-20130045966-A1 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | ATIC, NPPA, XPNPEP1 | L3MBTL1 1151/4885CASP1 802/4885HSD17B10 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.